Emerson Electric Co.

EMR

CIK 0000032604 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$4.35B
↑+4.1% +$171Mvs FY2024 (Q4)
Operating Income
$686M
↑+14.0% +$84Mvs FY2024 (Q4)
Net Income
$427M
↓-27.0% -$158Mvs FY2024 (Q4)
Gross Profit
$2.31B
↑+3.4% +$76Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
24/100
  • Profitability
    0Insufficient data
  • Liquidity
    19Current Ratio 0.88 (above 1.5 = solid)
  • Leverage
    79D/E 0.41 (under 0.5 = conservative)
  • Efficiency
    17Asset Turnover 0.42x (1.0+ = capital-efficient)
  • Growth
    30Revenue YoY +4.1% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project EMR's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

3%

Trailing 3-yr CAGR was 0.6%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$65.70
Total enterprise IV
$37.23B
Diluted shares
0.57B
Terminal PV
$26.24B (70% of total)
Year-5 FCF
$3.09B
YearProjected FCFDiscounted PV
+1$2.75B$2.50B
+2$2.83B$2.34B
+3$2.91B$2.19B
+4$3.00B$2.05B
+5$3.09B$1.92B
Terminal$42.25B$26.24B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$445M
investment in PP&E
Dividends paid (TTM)
$1.20B
cash returned to holders
Stock buybacks (TTM)
$518M
share count reduction
Stock-based comp (TTM)
$250M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$41.94B
everything owned
Stockholders' equity
$20.28B
shareholder claim
Net debt
$2.85B
LT debt minus cash

Recent performance · 71 quarters

Revenue↑+4.1% +$171M
$4.35B
Net Income↑+3.4% +$20M
$605M
Free Cash Flow↓-13.3% -$92M
$602M

Drill down